Selling Peptides Online? The Telehealth and FDA Issues Michigan Medical Practices Need to Navigate
Peptide therapy has moved from specialty clinics to the telehealth storefront. A patient can now fill out an online questionnaire, speak with a clinician by video, and have an injectable peptide shipped to their door. For physicians, nurse practitioners, med spa owners, and telehealth entrepreneurs in Southeast Michigan, the business model is attractive. The legal footing is far less settled.

The core problem is that two different bodies of law apply at once, and compliance with one does not satisfy the other. This post explains how Michigan’s telehealth rules and the FDA’s drug rules fit together, where the current enforcement focus is, and what to review before you launch or expand an online peptide offering.
Two Sets of Rules, Not One
Michigan’s telehealth law governs how care may be delivered remotely: consent, the standard of care, and who may prescribe. Federal drug law, enforced by the FDA, governs what may be prescribed, compounded, and sold. A flawless telehealth visit does not make an unapproved or improperly compounded product lawful, and a lawful product does not excuse a deficient telehealth process. Practices that focus on compliance for only one side are the ones that end up in front of regulators.
What Michigan’s Telehealth Law Requires
Michigan’s principal telehealth provisions appear at MCL 333.16283 et seq. In practice, the key requirements are these:
- Informed consent first. A health professional may not provide a telehealth service without first obtaining the patient’s informed consent. The practice should document consent in the medical record and apply the current Public Health Code, any profession-specific administrative rules, and generally applicable law governing consent for minors.
- A real clinical evaluation. The treating professional must obtain sufficient clinical information, using technology appropriate to the patient’s condition and the service provided, to satisfy the same standard of care and scope-of-practice requirements that apply to in-person treatment, while complying with applicable federal and state privacy and security requirements. Michigan does not impose a universal in-person-visit prerequisite, but an in-person examination may be required when the applicable standard of care cannot be met remotely, and a questionnaire alone may be insufficient to support diagnosis or prescribing.
- Same standard of care. The rules treat telehealth as the practice of the profession, with the same scope-of-practice limits and standard of care as in-person care.
- Prescribing limits. Only authorized prescribers may prescribe within their professional scope and any applicable supervision or delegation requirements; controlled-substance prescribing must also comply with Michigan law, MAPS obligations, the federal Ryan Haight Act, 21 U.S.C. § 829(e), and then-current DEA telemedicine rules.
- Licensure follows patient location. A Michigan license generally does not authorize you to treat patients located in other states.
A violation of these telehealth provisions can lead to restrictions or conditions on a professional’s ability to provide telehealth services, in addition to other discipline available under the Public Health Code.
Where Peptides Stand With the FDA
Most peptides sold online are not FDA-approved drugs for the uses being promoted. Eligibility to compound from a bulk drug substance depends on the applicable statutory pathway: section 503A, 21 U.S.C. § 353a(b)(1)(A), governs qualifying patient-specific compounding, while section 503B, 21 U.S.C. § 353b(a)(2)(A), separately governs registered outsourcing facilities; FDA approval of a finished drug, placement on a final bulks list, and treatment under an interim enforcement-discretion category are legally distinct.
Recent developments have created confusion:
- FDA has identified significant safety risks for certain nominated peptide substances, including BPC-157.
- The status of each nominated peptide should be checked against FDA’s current bulk-drug-substance materials as of publication, because withdrawal of a nomination or removal from an interim category does not establish FDA approval or statutory eligibility for compounding.
- Any Pharmacy Compounding Advisory Committee recommendation are advisory and are not the same as the FDA taking legally operative action.
Headlines about “reclassification” and “committee approval” are being used in peptide marketing. Before a practice relies on any of them, confirm what the FDA has actually done.
Enforcement Focuses on Telehealth Marketing
The FDA’s recent enforcement focus is not only on products but on how telehealth companies describe them. FDA warning letters and other enforcement materials have challenged marketing claims concerning compounded products, including claims that imply approval, generic status, or equivalence to an FDA-approved drug; any numerical enforcement summary should be tied to identified agency records and a stated cutoff date. The letters have targeted several recurring claims:
- Implying that a compounded product is the same as, or equivalent to, an FDA-approved drug.
- Describing a compounded drug as “generic.”
- Representing that a compounded product has been approved or evaluated by the FDA for safety and effectiveness.
- Obscuring who actually compounded the drug by selling it under the telehealth company’s own brand.
The FDA also launched a webpage for telehealth companies describing common promotional pitfalls. Although those letters concerned GLP-1 products, the same misbranding theory can apply to any compounded or unapproved peptide marketed online.
“Research Use Only” Is Not a Safe Harbor
Some online sellers label peptides “for research use only” or “not for human consumption.” FDA has issued multiple warning letters to online sellers using those labels where the surrounding promotional claims and distribution practices indicated an intended use in humans. A disclaimer does not control intended use when objective evidence, including website claims, dosing instructions, product presentation, or distribution practices, indicate that a product is intended for human use. Product pages that discuss weight loss or appetite, give dosing guidance, or sell injection supplies alongside the peptide may be relied upon by regulators.
For a licensed professional, the lesson is direct: sourcing from a “research” vendor and prescribing or administering the product to a patient is not a workaround. It can expose both the seller and the clinician.
Why Licensed Professionals Carry Extra Risk
A physician or nurse practitioner who serves as the prescriber or medical director for an online peptide business may face more than an FDA letter:
- Licensing discipline. The Public Health Code authorizes professional discipline on grounds that may include negligence, incompetence, unprofessional conduct, and violations of applicable law under MCL 333.16221, with sanctions available under MCL 333.16226; the particular ground depends on the conduct and profession involved.
- Federal liability. Introducing an unapproved new drug or a misbranded drug into interstate commerce may violate federal law and may support remedies including injunction, seizure, or criminal enforcement.
- Private claims. Manufacturers of approved drugs have sued compounders, med spas, medical practices, and telehealth providers, and patients injured by a product have their own claims.
Practical Steps for Practices
- Verify the product’s legal status. For each peptide, confirm whether it is FDA-approved, eligible for compounding, or neither, and document how you reached that conclusion.
- Know your pharmacy. Use a properly licensed pharmacy and confirm its authority to compound the specific substance under the applicable section 503A or 503B pathway; patient-specific prescriptions are generally central to section 503A, whereas registered outsourcing facilities operate under the distinct conditions of section 503B.
- Audit your website and ads. Remove claims of equivalence, “generic” descriptions, implied FDA approval, and any language suggesting a compounded product has been FDA-evaluated. Identify the compounding pharmacy clearly.
- Build a real telehealth workflow. Obtain and document informed consent, gather sufficient clinical information through technology appropriate to the patient and service, satisfy the applicable standard of care and prescribing requirements, and maintain records required by Michigan law and profession-specific rules.
- Check licensure for every patient location. Confirm that each clinician is licensed where the patient is physically located.
- Review your ownership and contracts. Have counsel review the structure among the clinician, any management company, and the pharmacy.
- Avoid “research” shortcuts. Do not source or administer products labeled for research use only.
When to Talk to a Health Care Attorney
It is far cheaper to answer these questions before launch. Consider a consultation if:
- You are planning to start or expand an online peptide or weight-loss telehealth program.
- You received an FDA warning letter or a state inquiry, or a pharmacy partner has questioned your marketing.
- You are a prescriber being asked to serve as medical director for a business you did not build.
- LARA has contacted you about a telehealth, prescribing, or advertising issue.
Frequently Asked Questions
Can I prescribe peptides through telehealth in Michigan? Michigan law allows licensed prescribers to prescribe through telehealth after obtaining informed consent and performing an appropriate evaluation. Whether a particular peptide may lawfully be compounded or sold is a separate federal question that must be answered first.
Does a “research use only” label protect a seller? The FDA has said it does not, when the seller’s website shows the product is intended for human use.
Can I describe a compounded product as the same as a brand-name drug? No. FDA warning letters have challenged unsupported claims that compounded products are the same as, equivalent to, or generic versions of FDA-approved drugs, but each marketing claim should be assessed under the applicable misbranding provisions, including 21 U.S.C. § 352, and the specific facts of the promotion.
If you operate or advise an online peptide or telehealth practice, the attorneys at Szura & Delonis, PLC represent health care professionals and businesses across Oakland, Wayne, Macomb, and Washtenaw Counties. Call (248) 716-3600 or contact us online to discuss your situation before a regulator does.
This post is intended for general informational purposes and does not constitute legal advice. FDA policy on peptides and federal and state telehealth requirements may change, and each practice’s obligations depend on the product, compounding pathway, prescriber’s professional authority, patient’s location, and then-current law as of the date of service. If you have questions about a telehealth program, a product’s legal status, or a regulatory inquiry, consult a health care attorney before taking action.










